ClinicalThought

Don’t Delay With Delta: Best Practices and Calls to Action in HDV

In this series of concise, engaging Medical Minutes and podcasts, hear from international experts on the global burden of HDV, risk factors and screening recommendations, new treatment options and current management recommendations, and the evolving therapeutic landscape. Gain patient perspectives to better understand the impact of disease and delays in diagnosis.

Norah Terrault, MD, MPH

Heiner Wedemeyer, MD

Cihan Yurdaydin, MD

ClinicalThought

First Things First: Why We Need Worldwide Improvement in Screening for HDV

View ClinicalThought

To link patients with hepatitis delta virus to care, we first must be able to identify them.

Cihan Yurdaydin, MD Released: March 8, 2022

ClinicalThought

Key Questions on Emerging Treatments for Hepatitis Delta

View ClinicalThought

Emerging treatment options for hepatitis delta virus are promising, but we still have more questions than answers regarding the optimal use of these agents around the globe.

Heiner Wedemeyer, MD Released: March 23, 2022

ClinicalThought

Overcoming Missed Opportunities for Hepatitis Delta Screening and Surveillance

View ClinicalThought

My thinking about HDV testing recommendations has shifted in recent years. Here’s why.

Norah Terrault, MD, MPH Released: May 18, 2022

Don’t Delay With Delta: Best Practices and Calls to Action in HDV

First Things First: Why We Need Worldwide Improvement in Screening for HDV

Key Questions on Emerging Treatments for Hepatitis Delta

Overcoming Missed Opportunities for Hepatitis Delta Screening and Surveillance

Leaving the CCO site